PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
April 5, 2024Cancer Research

Abstract LB055: IBI3001: A potentially first-in-class site-specifically conjugated B7-H3/EGFR bispecific ADC for multiple solid tumors

View Full Paper
Ask AI
Bookmark
Share

Authors

JGJian GuanXZXiao ZhangWWWeiwei Wu

Discussion

Loading...

Member takes

Overview

Preclinical study demonstrates robust antitumor activity of a B7-H3/EGFR bispecific ADC across multiple solid tumor xenografts, suggesting enhanced safety and efficacy.

Key Points

  • The bispecific antibody-drug conjugate IBI3001 delivers potent in vitro cytotoxicity across diverse solid tumor cells regardless of target receptor expression levels.
  • IBI3001 achieves a 282-hour half-life in mice and produces robust tumor growth inhibition across colorectal, breast, pancreatic, and lung cancer xenograft models.
  • Preclinical testing shows tolerability up to 90 mg/kg/week in cynomolgus monkeys and reduces on-target toxicity; non-human primate model; further clinical testing needed.

Cite This Study

Guan et al. (2024) studied this question.

synapsesocial.com/papers/68e70542b6db64358767eaa9https://doi.org/10.1158/1538-7445.am2024-lb055
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract LB056: IBI334, a novel ADCC-enhanced B7-H3/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors2024 · 2 citations
  2. 2Abstract 6365: The bispecific antibody KA-3008, targeting both EGFR and B7H3, increases internalization and minimizes on-target, off-tumor toxicity2024 · 1 citations
  3. 3Abstract 6366: The triple-specific antibody KA-3009 against EGFR, B7H3, and 4-1BB specifically enhances T cell activity within the tumor2024
  4. 4Abstract LB051: BCG048, a novel bispecific dual-payload ADC targeting ITGB6 and B7H3, exhibited potent efficacy in patient-derived tumor xenograft models2026
  5. 5Abstract LB355: ICP-B794, a B7H3-targeting ADC with a novel linker-payload, demonstrated superior anti-tumor activity and large therapeutic window in preclinical studies2026